Anika Therapeutics, Inc. (ANIK)

Anika Therapeutics, Inc. focuses on joint preservation, offering solutions for osteoarthritis pain management, regenerative solutions, and soft tissue repair. The company leverages its hyaluronic acid (HA) technology platform to develop and commercialize a range of orthopedic and non-orthopedic products.

43/100 AI Score MCap $150.27M Vol 113.6K

Company Overview

CEOCheryl Renee Blanchard
Employees288
HeadquartersBedford, MA, US
IPO Year1993

Anika Therapeutics pioneers early intervention orthopedic care with its HA-based joint preservation solutions, targeting the osteoarthritis pain management and regenerative medicine markets. With a diverse product portfolio and international reach, Anika offers investors a unique opportunity in the growing orthopedic device sector, despite current profitability challenges.

Investment Thesis

Anika Therapeutics presents a compelling investment opportunity due to its established presence in the growing joint preservation market and its innovative HA-based product portfolio. Despite a current negative P/E ratio of -4.55 and a profit margin of -40.8%, Anika's high gross margin of 83.0% signals strong pricing power and operational efficiency that can be leveraged as the company scales. Key value drivers include the increasing prevalence of osteoarthritis and the growing demand for minimally invasive orthopedic procedures. Upcoming catalysts include potential regulatory approvals for new products and expansion into emerging markets. The company's low beta of 0.43 suggests lower volatility compared to the overall market, making it an attractive option for risk-averse investors seeking exposure to the healthcare sector. Successful execution of its growth strategies and a return to profitability could drive significant shareholder value.

Key Highlights

  • Gross Margin of 83.0% indicates strong pricing power and efficient cost management in product manufacturing.
  • Market Cap of $0.15B suggests potential for growth and appreciation as the company expands its market share.
  • Beta of 0.43 indicates lower volatility compared to the market, offering a degree of stability for investors.
  • Focus on Hyaluronic Acid (HA) technology provides a competitive edge in the osteoarthritis pain management and regenerative solutions markets.
  • International presence allows for revenue diversification and access to a broader customer base.

Competitors

Strengths

  • Proprietary HA technology platform
  • Diverse product portfolio
  • Established brands in OA pain management
  • International presence

Weaknesses

  • Negative profit margin
  • Reliance on HA technology
  • Limited brand recognition outside orthopedics
  • Small market capitalization

Catalysts

  • Upcoming: Potential regulatory approvals for new products in the orthopedic and regenerative medicine space.
  • Ongoing: Expansion of sales and marketing efforts in key geographic markets.
  • Ongoing: Continued investment in research and development to create innovative products.
  • Ongoing: Strategic partnerships with leading orthopedic surgeons and hospitals.

Risks

  • Potential: Competition from established medical device companies with greater resources.
  • Potential: Regulatory hurdles and delays in product approvals.
  • Ongoing: Economic downturns that could reduce healthcare spending.
  • Ongoing: Product liability claims and recalls.
  • Ongoing: Dependence on key personnel and suppliers.

Growth Opportunities

  • Expansion of OA Pain Management Products: The market for osteoarthritis pain management is projected to reach $8.5 billion by 2028, driven by an aging population and rising obesity rates. Anika can capitalize on this trend by expanding the reach of its existing OA pain management products, such as Monovisc and Orthovisc, into new geographic markets and by developing next-generation HA-based therapies with improved efficacy and duration of action. This expansion requires strategic partnerships and targeted marketing campaigns to increase product awareness and adoption.
  • Development of Regenerative Solutions: The regenerative medicine market is experiencing rapid growth, with a projected market size of $55 billion by 2027. Anika can leverage its HA technology platform to develop innovative regenerative solutions for cartilage repair, bone regeneration, and soft tissue healing. This includes investing in research and development to create novel products that stimulate tissue regeneration and reduce the need for invasive surgical procedures. Success in this area would position Anika as a leader in the emerging field of regenerative orthopedics.
  • Strategic Acquisitions and Partnerships: Anika can accelerate its growth by acquiring complementary technologies and businesses in the orthopedic and regenerative medicine space. This includes targeting companies with innovative products, strong distribution networks, or specialized expertise in areas such as sports medicine or joint reconstruction. Strategic partnerships with leading orthopedic surgeons and research institutions can also enhance Anika's product development efforts and strengthen its market position. These initiatives will allow Anika to expand its product offerings and reach new customer segments.
  • Geographic Expansion into Emerging Markets: Emerging markets, such as China and India, represent significant growth opportunities for Anika due to their large populations and increasing healthcare spending. Anika can expand its presence in these markets by establishing local distribution networks, partnering with local manufacturers, and adapting its products to meet the specific needs of these markets. This requires a deep understanding of the regulatory landscape and cultural nuances of each market. Successful expansion into emerging markets would diversify Anika's revenue streams and reduce its reliance on developed markets.
  • Expansion into Non-Orthopedic Applications: Anika can leverage its HA technology platform to expand into non-orthopedic applications, such as wound care, ophthalmology, and aesthetics. The market for HA-based products in these areas is substantial and growing, driven by increasing demand for minimally invasive procedures and advanced medical treatments. This diversification strategy would reduce Anika's reliance on the orthopedic market and create new revenue streams. This requires investment in research and development to adapt its HA technology for these new applications.

Opportunities

  • Expansion into emerging markets
  • Development of regenerative solutions
  • Strategic acquisitions and partnerships
  • Expansion into non-orthopedic applications

Threats

  • Competition from larger medical device companies
  • Regulatory changes and reimbursement pressures
  • Product liability claims
  • Economic downturns

Competitive Advantages

  • Proprietary hyaluronic acid (HA) technology platform.
  • Established brands in the OA pain management market (Monovisc, Orthovisc, Cingal, Hyvisc).
  • Extensive product portfolio covering various orthopedic applications.
  • Strong relationships with orthopedic surgeons and hospitals.

About

Founded in 1983 and headquartered in Bedford, Massachusetts, Anika Therapeutics, Inc. is a joint preservation company dedicated to creating and delivering advancements in early intervention orthopedic care. The company operates in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Anika's core strength lies in its proprietary hyaluronic acid (HA) technology platform, which forms the basis for its diverse range of products. These products are developed, manufactured, and commercialized across the United States, Europe, and internationally. Anika's OA pain management product family includes well-known brands such as Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to provide relief from osteoarthritis-related pain. The company also offers a comprehensive joint preservation and restoration product family, featuring approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. Beyond orthopedics, Anika has expanded into non-orthopedic applications, offering HA-based products for adhesion barriers, advanced wound care, ophthalmic solutions, and ear, nose, and throat applications. This diversified approach allows Anika to address a broader range of medical needs and reduce its reliance on a single market segment. Anika's commitment to innovation and strategic expansion has positioned it as a key player in the evolving landscape of orthopedic and regenerative medicine.

What They Do

  • Develop, manufacture, and commercialize orthopedic and non-orthopedic products.
  • Offer osteoarthritis (OA) pain management solutions.
  • Provide regenerative solutions for cartilage and bone repair.
  • Offer soft tissue repair products for sports medicine.
  • Develop bone-preserving joint technologies.
  • Create HA-based products for wound care and ophthalmic applications.
  • Offer products for ear, nose, and throat (ENT) applications.

Business Model

  • Develop and manufacture products based on hyaluronic acid (HA) technology.
  • Sell products directly to hospitals, clinics, and orthopedic surgeons.
  • Generate revenue through product sales in the United States, Europe, and internationally.
  • Invest in research and development to create new and improved products.

Industry Context

Anika Therapeutics operates within the medical device industry, specifically focusing on joint preservation and regenerative medicine. The market for osteoarthritis pain management is substantial and growing, driven by an aging population and increasing obesity rates. The competitive landscape includes companies offering similar HA-based therapies and surgical solutions. Anika differentiates itself through its diverse product portfolio and focus on early intervention orthopedic care. The industry is characterized by ongoing innovation, with companies continually developing new and improved treatments for musculoskeletal conditions. Anika's commitment to research and development positions it to capitalize on these trends and maintain a competitive edge.

Key Customers

  • Orthopedic surgeons
  • Hospitals and clinics
  • Patients with osteoarthritis and other musculoskeletal conditions
  • Wound care specialists
  • Ophthalmologists
AI Confidence: 71% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $28M -$2M $0.00
Q2 2025 $28M -$4M $0.00
Q1 2025 $26M -$5M $0.00
Q4 2024 $31M -$22M $0.00

Source: Company filings

Chart & Info

Price Chart

Anika Therapeutics, Inc. (ANIK) stock price: $10.42 (+0.00, +0.00%)

Why Bull

  • •Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the business believe in its potential.
  • •Community sentiment has shifted positively, with discussions highlighting the innovative pipeline and its potential to address unmet medical needs.
  • •Recent partnerships and collaborations have strengthened market perception, positioning Anika as a key player in the therapeutic space.
  • •Analysts are increasingly recognizing the company's advancements in regenerative medicine, which could lead to significant growth opportunities.

Why Bear

  • •Concerns over the competitive landscape have emerged, as new entrants could challenge Anika's market share and innovation.
  • •Recent earnings reports have shown volatility, raising questions about the sustainability of revenue growth in the near term.
  • •Social sentiment has seen some bearish discussions, with investors worried about regulatory hurdles that could delay product launches.
  • •Market perception remains cautious due to broader economic factors affecting healthcare spending, potentially impacting Anika's sales.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
NaN

Rationale

AI-generated technical analysis for ANIK including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Anika Therapeutics, Inc. (ANIK) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for ANIK.

Make a Prediction

Set your price target for Anika Therapeutics, Inc. (ANIK), choose a timeframe, and track your prediction accuracy.

Current price: $10.42

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ANIK.

Price Targets

Wall Street price target analysis for ANIK.

Insider Flow (30d)

Griffin Stephen D.
Insider
3 weeks ago
BOUGHT
440,609 shares

MoonshotScore

42.5/100

Score Factors

  • Revenue Growth 2/100

    Revenue declined -28.1% YoY, signaling shrinking demand or market headwinds.

  • Gross Margin 8/100

    Gross margin at 55.3% indicates good unit economics and healthy profitability per sale.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates ANIK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Anika Therapeutics, Inc. do?

Anika Therapeutics is a joint preservation company that develops, manufactures, and commercializes orthopedic and non-orthopedic products based on its proprietary hyaluronic acid (HA) technology. The company's primary focus is on osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Anika's products are sold to hospitals, clinics, and orthopedic surgeons in the United States, Europe, and internationally. The company aims to provide innovative solutions that improve patient outcomes and reduce the need for invasive surgical procedures, positioning itself as a key player in the evolving landscape of orthopedic care.

Is ANIK stock a good buy?

ANIK stock presents a mixed investment profile. While the company boasts a high gross margin of 83.0% and a low beta of 0.43, its negative P/E ratio of -4.55 and profit margin of -40.8% raise concerns about profitability. The company's focus on the growing joint preservation market and its innovative HA-based product portfolio offer potential for future growth. However, investors should carefully consider the company's financial performance and competitive landscape before making an investment decision. Successful execution of its growth strategies and a return to profitability are crucial for driving shareholder value.

What are the main risks for ANIK?

Anika Therapeutics faces several key risks, including competition from larger medical device companies with greater resources, regulatory hurdles and delays in product approvals, and potential product liability claims. The company's reliance on its HA technology platform also poses a risk, as any adverse events or negative publicity related to HA could significantly impact its business. Additionally, economic downturns could reduce healthcare spending and negatively affect demand for Anika's products. Investors should carefully consider these risks before investing in ANIK stock.

Is ANIK a good stock to buy?

Whether ANIK is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the ANIK MoonshotScore?

The MoonshotScore for ANIK is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is ANIK data updated?

ANIK stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to ANIK is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for ANIK?

Growth catalysts for Anika Therapeutics, Inc. (ANIK) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Anika Therapeutics, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are ANIK's main competitors?

Anika Therapeutics, Inc. (ANIK) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether ANIK has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about ANIK?

Wall Street analyst coverage for ANIK includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is ANIK's market cap?

Market capitalization (market cap) for ANIK is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows ANIK's current market cap alongside enterprise value and other valuation metrics.

How has ANIK stock performed recently?

ANIK's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing ANIK's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in ANIK?

Key risk categories for ANIK include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures ANIK's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling ANIK?

Insider trading activity for ANIK tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is ANIK a good stock for beginners?

Anika Therapeutics, Inc. (ANIK) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is ANIK for first-time investors?

Every stock carries risk, including Anika Therapeutics, Inc. (ANIK). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like ANIK.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Financial data may be outdated. Stock data pending update.
Data Sources
profilefundamentalsexistingCopy